{"id":2673,"date":"2019-08-01T12:02:00","date_gmt":"2019-08-01T10:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/nochmals-eisengaben-bei-herzinsuffizienz-nur-bei-nachweis-eines-absoluten-eisenmangels"},"modified":"2022-03-17T14:13:58","modified_gmt":"2022-03-17T13:13:58","slug":"nochmals-eisengaben-bei-herzinsuffizienz-nur-bei-nachweis-eines-absoluten-eisenmangels","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/nochmals-eisengaben-bei-herzinsuffizienz-nur-bei-nachweis-eines-absoluten-eisenmangels","title":{"rendered":"Nochmals: Eisengaben bei Herzinsuffizienz nur bei Nachweis eines absoluten Eisenmangels?"},"content":{"rendered":"<p>Die europ\u00e4ische kardiologische Gesellschaft (ESC) empfiehlt bei symptomatischen Patienten mit Herzinsuffizienz, reduzierter linksventrikul\u00e4rer Auswurffraktion (HFrEF = Heart Failure with reduced Ejection Fraction) und Eisenmangel (EM) eine intraven\u00f6se Eisengabe in Betracht zu ziehen, vorzugsweise mit Fe-Carboxymaltose. Ziel dieser Behandlung ist es, die Symptome der Patienten zu lindern und deren Lebensqualit\u00e4t zu verbessern (Empfehlungsgrad 2A, Evidenzlevel A; [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die europ\u00e4ische kardiologische Gesellschaft (ESC) empfiehlt bei symptomatischen Patienten mit Herzinsuffizienz, reduzierter linksventrikul\u00e4rer Auswurffraktion (HFrEF = Heart Failure with reduced Ejection Fraction) und Eisenmangel (EM) eine intraven\u00f6se Eisengabe in Betracht zu ziehen, vorzugsweise mit Fe-Carboxymaltose. Ziel dieser Behandlung ist es, die Symptome der Patienten zu lindern und deren Lebensqualit\u00e4t zu verbessern (Empfehlungsgrad 2A, Evidenzlevel A; [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5258,5256,4922,5257,1547,1546,1542,4921,1540,180,5259,1538],"class_list":["post-2673","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-berliner-blau","tag-biostat-chf-studie","tag-confirm-hf-studie","tag-define-hf-studie","tag-eisen","tag-eisencarboxymaltose","tag-eisenmangel","tag-fair-hf-studie","tag-ferritin","tag-herzinsuffizienz","tag-ironout-hf-studie","tag-transferrin-saettigung"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2673"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2673\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}